MacroGenics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. Its products include Margetuximab, a monoclonal antibody that targets human epidermal growth factor receptor 2-expressing tumors, including breast, gastroesophageal, bladder, and other cancers; MGA271, an Fc-optimized monoclonal antibody for various solid tumor types; MGD006, a humanized dual affinity re-targeting (DART) molecule for the treatment of hematologic cancers; and MGD007, a DART protein to treat colorectal cancer. The company's products also comprise Teplizumab, a humanized anti-CD3 monoclonal antibody for the treatment of Type 1 Diabetes; and MGD010, a DART-based molecule for autoimmune diseases. The company has strategic collaborations primarily with Les Laboratoires Servier and Institut de Recherches Servier; Gilead Sciences, Inc.; Boehringer Ingelheim International GmbH; and Pfizer, Inc. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.
Address
9640 Medical Center Drive
ROCKVILLE, MD 20850
United States
ROCKVILLE, MD 20850
United States
Website
www.macrogenics.comKey stats and ratios
| Q2 (Jun '13) | 2012 | |
| Net profit margin | -2.76% | 13.10% |
| Operating margin | -2.44% | 12.86% |
| EBITD margin | - | 14.36% |
| Return on average assets | -2.96% | 14.36% |
No comments:
Post a Comment